Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated)

BACKGROUND: A genomic biomarker identifying patients likely to benefit from drotrecogin alfa (activated) (DAA) may be clinically useful as a companion diagnostic. This trial was designed to validate biomarkers (improved response polymorphisms (IRPs)). Each IRP (A and B) contains two single nucleotid...

Descripción completa

Detalles Bibliográficos
Autores principales: Annane, Djillali, Mira, Jean Paul, Ware, Lorraine B, Gordon, Anthony C, Sevransky, Jonathan, Stüber, Frank, Heagerty, Patrick J, Wellman, Hugh F, Neira, Mauricio, Mancini, Alexandra DJ, Russell, James A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403963/
https://www.ncbi.nlm.nih.gov/pubmed/22694772
http://dx.doi.org/10.1186/2110-5820-2-15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403963/
https://www.ncbi.nlm.nih.gov/pubmed/22694772
http://dx.doi.org/10.1186/2110-5820-2-15

Ejemplares similares